MHRA develops AdvanceGxP manufacturing service

MHRA develops AdvanceGxP manufacturing service

The MHRA is developing earlier support for novel medicines manufacturing. AdvanceGxP will initially test practical regulatory engagement for emerging production technologies, without replacing formal inspections, approvals or existing statutory requirements.


The Medicines and Healthcare products Regulatory Agency (MHRA) is developing a regulatory support service intended to help organisations address manufacturing compliance requirements earlier when introducing novel medicines production technologies.

AdvanceGxP will initially focus on technologies whose development raises questions about the application of established Good Practice principles. The regulator has secured funding from the Office for Life Sciences to develop and test the service.

The initiative was announced at the DIA–MHRA Global Summit in London on 17 November 2026, with the MHRA publishing further information the following day.

The proposed service is intended to provide earlier access to practical expertise concerning manufacturing processes, facilities, equipment, quality systems and other regulatory considerations that may be difficult to resolve through existing published guidance alone.

The MHRA has identified personalised medicines production, manufacturing close to patients, space-based manufacturing and the use of artificial intelligence, robotics and automation among the technologies relevant to its initial development.

AdvanceGxP remains under development. The regulator has not opened applications for formal support, and organisations registering their interest are not guaranteed participation in its testing or pilot activities.

Manufacturing medicines involves requirements that extend beyond achieving a specified output or demonstrating that equipment can perform an intended operation.

Processes must be designed and controlled to produce medicines that meet appropriate quality standards. Manufacturers must also maintain evidence that their facilities, equipment, materials, procedures and personnel are suitable for the activities being undertaken.

Good Manufacturing Practice provides a framework for those responsibilities, including requirements affecting production controls, documentation, quality assurance and the investigation of deviations.

Established pharmaceutical manufacturing operations generally develop their facilities and processes within well-understood regulatory arrangements. Novel technologies can create difficulties when existing examples and detailed guidance do not closely match the proposed production model.

Personalised medicines illustrate the difference. Certain treatments may need to be manufactured in small quantities for individual patients or defined patient groups, rather than in large batches distributed through conventional supply chains.

Some technologies may also require manufacturing closer to hospitals or clinical facilities, particularly where product characteristics or short shelf lives limit the opportunities for centralised production.

These arrangements introduce questions about how production sites are controlled, how quality responsibilities are assigned and how manufacturing records are maintained across the relevant operations.

A smaller production facility is still subject to applicable quality requirements. The scale and location of the process may change how those requirements are implemented, but they do not eliminate the need to demonstrate adequate control.

Automation introduces another set of engineering considerations. An automated manufacturing system may undertake material handling, process control, measurement and other activities with limited direct operator intervention.

The equipment’s behaviour must remain consistent with the approved manufacturing process, including the conditions under which an operation is permitted to start, continue or stop.

Sensors, control systems and associated software can influence critical processing parameters. Their suitability therefore depends on the intended application and the consequences of incorrect operation.

Manufacturers may need to establish how equipment is qualified, how the process is validated and how deviations or unexpected results are identified and managed.

Artificial intelligence can introduce additional complexity where models interpret manufacturing information or influence decisions affecting a production process.

The requirements will depend on the role the technology performs and the risks associated with its use. An AI application used to organise information may raise different questions from one proposed for a critical process control function.

The MHRA has not announced a universal approval pathway for AI-controlled pharmaceutical production through AdvanceGxP.

Instead, it intends to help developers examine the applicable Good Practice principles and identify regulatory questions while a technology is still being designed.

Earlier engagement could alter the sequence of decisions in a manufacturing project. Facilities, equipment and production processes are often specified before every issue affecting validation and compliance has been resolved.

Discovering a significant incompatibility after equipment has been installed may require design changes, additional testing or modifications to the manufacturing environment.

Addressing those questions during development could reduce some of that rework, although AdvanceGxP has not yet demonstrated a quantified reduction in project costs or approval times.

Its proposed scope also extends to innovative approaches intended to improve sustainability in chemistry, manufacturing and controls.

The regulatory implications of such changes depend on the underlying process. Substituting materials, modifying reaction conditions or introducing a different production method may affect product quality, impurity profiles or the evidence needed to establish process consistency.

A technically promising alternative must therefore be assessed against the requirements applying to the medicine being produced.

The MHRA plans to test how AdvanceGxP should operate alongside its existing services and regulatory responsibilities.

It will develop eligibility criteria and access arrangements, recruit relevant expertise and examine the demand for support among organisations working on emerging manufacturing technologies.

Capacity during the early phases will be limited. The agency has confirmed that access during testing and pilot activities will be free of charge, while the arrangements for any subsequent permanent service remain to be determined.

Registering an expression of interest is separate from submitting an application for regulatory advice. Participation in the development process does not establish that a product, facility or manufacturing method has been accepted by the regulator.

AdvanceGxP will not provide pre-inspection clearance, replace formal inspections or guarantee future regulatory approval.

The initiative sits alongside wider efforts to strengthen UK medicines production, including work examining the country’s existing manufacturing capabilities and areas of specialist capacity.

Recent analysis of UK contract medicines manufacturing identified established production capabilities alongside gaps affecting certain technologies and stages of manufacture.

AdvanceGxP addresses a different part of the manufacturing environment. Its objective is to provide earlier guidance on regulatory questions arising during technological development, rather than directly funding factory construction or adding production capacity.

The MHRA will use the initial development and testing phases to determine how the service can be delivered and whether it should be expanded.

Manufacturers considering the relevant technologies must continue to use existing regulatory routes until the new arrangements are formally established. The next milestone is the completion of service development and the establishment of its initial pilot operation.


Stories for you


  • Kishorn floating wind manufacturing plans advance

    Kishorn floating wind manufacturing plans advance

    Slipform Engineering has advanced plans for Kishorn wind foundation manufacturing. The proposed factory could produce 36 concrete floating foundations annually, supported by manufacturing simulations and a separate demonstration facility being developed at Hunterston.


  • Nordex signs wind frameworks with Vattenfall

    Nordex signs wind frameworks with Vattenfall

    Nordex and Vattenfall agreed frameworks for future European wind projects. The agreements cover Germany and Britain until 2029 initially, with a possible two-year extension, but no firm turbine quantities or contract values have been disclosed.